<DOC>
	<DOCNO>NCT01174199</DOCNO>
	<brief_summary>RATIONALE : Temsirolimus vorinostat may stop growth tumor cell block enzymes need cell growth . Giving temsirolimus together vorinostat may kill tumor cell . PURPOSE : This phase I trial study side effect best dose temsirolimus vorinostat treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Temsirolimus Vorinostat Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety , tolerability recommend Phase II dose temsirolimus combination vorinostat patient metastatic , hormone refractory , chemoresistant prostate cancer . II . To obtain preliminary evidence response prostate cancer patient treat temsirolimus vorinostat . SECONDARY OBJECTIVES : I . To determine partial complete objective response rate metastatic hormone-refractory , chemo-resistant prostate cancer patient measurable disease treat temsirolimus vorinostat . II . To determine progression free survival overall survival patient metastatic hormone refractory , chemo-resistant prostate cancer . III . To determine PSA response , duration PSA response , time PSA progression , PSA double time PSA slope metastatic hormone refractory , chemo-resistant prostate cancer patient treat temsirolimus vorinostat . IV . To assess change expression level bone remodel marker ( N telopeptides bone alkaline phosphatase ) angiogenesis-related gene protein expression ( VEGF/HIF1-alpha ) blood circulate tumor cell , available , tissue , correlate cancer treatment relate outcomes . V. To assess change tumor metabolism FDG/IIC-Choline PET/CT scan . OUTLINE : Patients receive oral vorinostat daily day 1-14 temsirolimus IV day 1 , 8 , 15 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day every 3 month thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Patients must histologically confirm diagnosis adenocarcinoma prostate hormone refractory evidence progressive metastatic disease follow docetaxel treatment follow : Increased serum prostatespecific antigen ( PSA ) level confirm 3 consecutive PSA measurement ( least 2 week apart ) , first sample take least 6 week bicalutamide megestrol acetate withdrawal AND/OR Progression bidimensionally measurable soft tissue ( nodal ) metastasis CT scan MRI within past 4 week AND/OR Progression bone disease least two new bone lesion bone scan confirm second bone scan Patients without persist &gt; = grade 2 hematological/nonhematological toxicity previous treatment would preclude evaluation toxic effect study treatment.Grade 1 residual toxicity acceptable . Patients prior therapy least 4 week start study treatment Prior palliative radiation metastatic lesion ( ) permit , provide least one measurable and/or evaluable lesion ( ) radiate Castrate level serum testosterone ( = &lt; 50 ng/dL 1.0 mmol/L ) confirm within two week prior Day 1 treatment . Testosterone level require patient bilateral orchiectomy ECOG performance status 01 Life expectancy great 6 month Absolute neutrophil count &gt; = 1,500/mm^3 Platelets &gt; = 100,000/mm^3 Hgb &gt; = 9g/L Total bilirubin = &lt; 1.5 x laboratory upper limit normal ( ULN ) AST ( SGOT ) /ALT ( SGPT ) &lt; = 2.5 x laboratory ULN Creatinine = &lt; 1.5 x laboratory ULN calculate creatinine clearance &gt; = 50 ml/min Serum amylase = &lt; ULN ( If &gt; ULN , confirm pancreatic amylase &lt; 1.1 ukat/L serum lipase &lt; ULN ) PT/INR &lt; = 1.5 Urine protein &lt; 1+ &gt; = 1 24hour urine protein obtain &lt; 1000 mg Serum cholesterol &lt; ULN without treatment hyperlipidemia ; &gt; ULN untreated , may rescreened eligibility treatment Eligibility patient receive medication substance know affect potential affect activity pharmacokinetics temsirolimus determine follow review case Principal Investigator Patients , sexually active , agree use adequate contraceptive method ( barrier contraceptive spermicide , vasectomy , abstinence ) prior study entry duration study participation Ability understand willingness sign write informed consent document No evidence ( &gt; = 5 year ) prior malignancy except successfully treat basal cell squamous cell carcinoma skin Exclusion Prior use HDAC mTOR inhibitor Patients know brain metastases Any medical condition , include presence laboratory abnormality , confound ability interpret data study place patient unacceptable risk participates study History allergic reaction attribute compound similar chemical biologic composition vorinostat temsirolimus Concurrent use anticancer agent treatment except LHRH antagonist Uncontrolled intercurrent illness include , limited following : ( ) Ongoing active infection include viral hepatitis , ( b ) Symptomatic congestive heart failure ( New York Association Class II , III , IV ) , ( c ) unstable angina pectoris require nitrate therapy , ( ) prior myocardial infarction , ( e ) severe uncontrolled ventricular cardiac arrhythmia , ( f ) uncontrolled hypertension ( define blood pressure &gt; 160 mmHg systolic and/or &gt; 90 mmHg diastolic medication ) , ( g ) electrocardiographic evidence acute ischemia ( h ) Psychiatric illness/social situation would limit compliance study requirement Known positive serology HIV know history HIV potential pharmacokinetic unforeseen toxicity morbidity immunocompromised patient Any treatment modality , include radiation surgery , discontinue least 4 week prior treatment study Chronic Hepatitis advance , decompensated hepatic disease cirrhosis liver history chronic virus hepatitis know viral hepatitis carrier ( patient recover Hepatitis A allow enter study ) Simultaneous participation study involve investigational drug participate study le 4 week prior treatment study No investigational commercial agent therapy describe study may administer intent treat patient 's malignancy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>